Document is current

Article History

Accepted: 24 October 2022

First Online: 18 November 2022

Change Date: 12 December 2022

Change Type: Update

Change Details: In the version of this article initially published, the incorrect journal (<i>J. Pain</i>) was listed for ref. 134, which has now been corrected (<i>Pain Rep.</i>) in the HTML and PDF versions of the article.

Competing interests

: R.B. has received R.B. has received research funding from EU Projects Europain (115007), DOLORisk (633491), IMI Paincare (777500), the German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), German Research Network on Neuropathic Pain (01EM0903), Pfizer, Grünenthal, Mundi Pharma, Alnylam, Zambon, Bayer, Sanofi Aventis. He has been a speaker for Pfizer, Sanofi Aventis, Grünenthal, Mundipharma, Lilly, Desitin, Teva, Bayer, MSD, Seqirus, Novartis, TAD, Eva, Takeda, Ology, Ever, Amicus, Novo Nordisk, Chiesi, Stada, Hexal, Viatris. He has acted as a consultant for Pfizer, Sanofi Aventis, Grünenthal, Lilly, Novartis, Bristol-Myers Squibb, Biogenidec, AstraZeneca, Daiichi Sankyo, Glenmark, Seqirus, Teva, Genentech, Mundipharma, Galapagos, Kyowa Kirin, Vertex, Biotest, Celgene, Desitin, Regeneron, Theranexus, Abbott, Bayer, Akcea, Asahi Kasei, AbbVie, Air Liquide, Alnylam, Lateral, Hexal, Angelini, Janssen, SIMR, Confo, Merz, Neumentum, Hoffmann-La Roche, AlgoTherapeutix, Nanobiotix, AmacaThera. M.C. is a councillor at the International Society for the Study of Pain (IASP), a board member of the Neuropathic Pain Special Interest Group of IASP and a board member of the Neuropathic Pain Consortium (SIG of Peripheral Nerve Society). D.L.B. has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the past 2 years. He has received research funding from Lilly and AstraZeneca. He is an inventor for patent application ‘A method for the treatment or prevention of pain or excessive neuronal activity or epilepsy’ (application no. US16/337,428). He is a member of the Medical Reseach Council Neuroscience and Mental Health Board for which he receives reimbursement. He is an executive member of the Neuropathic Pain Special Interest Group of IASP. S.D.D.-H. has consulted with Ionis and Alnylam Pharmaceuticals over the past 2 years and is a board member of the Neuropathic Pain Special Interest Group of IASP. A.H.D. declares no competing interests.